3 research outputs found
Additional file 1: Figure S1. of ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T
Melting analysis of IEDAT qPCR amplicons. During SYBR green qPCR of the IEDAT samples, although only one PCR product was observable by melting step at the end of the experimental, some Tm discrepancies were noted among the samples. A different kind of ATMdexa1 target was probably amplified without affecting the PCR performance. (TIFF 41 kb
Blood levels of PHE in different forms of HPA.
<div><p>Values are expressed as means + S.E.M. N=6 for group.</p>
<p>*,*** p<0.05, 0.001 from Cntr mice.</p></div
Additional file 1: Figure S1. of Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4Â years: results from the SPARK open-label, multicentre, randomized phase IIIb trial
Summary of neuromotor developmental milestones – ITT population. Data show (a) the proportion of patients with normal development in the area of assessment at baseline, (b) Week 12, and (c) Week 26 treated with sapropterin plus the Phe-restricted diet, or Phe-restricted diet alone. P-values show comparison of results between treatment groups at Week 26 using the chi-squared test. Table S1. PAH genotypes of sapropterin responders (n=37). (DOCX 180 kb